{
    "clinical_study": {
        "@rank": "144702", 
        "acronym": "SIGN", 
        "arm_group": {
            "arm_group_label": "KPT-330", 
            "arm_group_type": "Experimental", 
            "description": "Oral KPT-330  at 50 mg/m\u00b2 twice weekly (Monday/ Wednesday or Tuesday/ Thursday or Wednesday/Friday)"
        }, 
        "brief_summary": {
            "textblock": "The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in patients\n      with advanced or metastatic gynaecological cancers by disease control rate (complete\n      response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks,\n      assessed according to RECIST 1.1 criteria). Three cohorts are planned: ovarian carcinoma,\n      endometrial carcinoma, and cervical carcinoma."
        }, 
        "brief_title": "Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Carcinoma", 
            "Endometrial Carcinoma", 
            "Cervical Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Uterine Cervical Neoplasms", 
                "Endometrial Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ovarian, fallopian tube or peritoneal carcinoma: both platinum refractory and\n             platinum resistant  patients, who have received \u2265 1 lines of chemotherapy for\n             relapsed disease (i.e., \u22652 lines of chemotherapy in total).\n\n          -  Endometrial carcinoma: patients must have received \u2265 1 line of chemotherapy for\n             relapsed or advanced (stage IVb) disease.\n\n          -  Cervical carcinoma: patients must have received \u2265 1 lines of chemotherapy for\n             relapsed or advanced (stage IVb) disease.\n\n          -  Must have either measurable disease (RECIST 1.1) or evaluable disease outside\n             irradiated field on CT/MRI. A rise in CA-125 or other tumor marker alone is not\n             sufficient.\n\n          -  ECOG performance status of 0-1.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Able to swallow and retain oral medication.\n\n        Exclusion Criteria:\n\n          -  Evidence of complete or partial bowel obstruction.\n\n          -  All non-epithelial cancers of the ovary, fallopian tube, peritoneum, endometrium or\n             cervix as well as neuro-endocrine tumors are excluded.\n\n          -  Radiation (except planned or ongoing palliative radiation to bone outside of the\n             region of measurable disease) \u2264 3 weeks prior to C1D1.\n\n          -  Chemotherapy, immunotherapy or systemic anticancer therapy \u2264 3 weeks prior to C1D1.\n\n          -  Major surgery within 4 weeks before C1D1."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02025985", 
            "org_study_id": "KCP-330-005"
        }, 
        "intervention": {
            "arm_group_label": "KPT-330", 
            "intervention_name": "KPT-330", 
            "intervention_type": "Drug", 
            "other_name": "selinexor"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Karyopharm", 
            "KPT-330", 
            "Selinexor", 
            "SIGN", 
            "ovarian cancer", 
            "endometrial cancer", 
            "cervical cancer"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Ignace Vergote, M.D.", 
                "phone": "+32 16344635"
            }, 
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "zip": "31 16 34 19 98"
                }, 
                "name": "University Hospitals Leuven"
            }, 
            "investigator": {
                "last_name": "Ignace Vergote, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies", 
        "other_outcome": {
            "description": "Will be evaluated after the first 4 weeks on study treatment and then every 8 weeks while on study treatment.", 
            "measure": "Evaluate Quality of Life (QoL)", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline on the EORTC QLW-C30 at 4 weeks and then every 8 weeks thereafter."
        }, 
        "overall_official": {
            "affiliation": "University Hospitals, Leuven", 
            "last_name": "Ignace Vergote, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Denmark: Danish Health and Medicines Authority"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Optional PET/CT or CT/MRI after 6 weeks of treatment. Required CT/MRI scans after 12 weeks on treatment and approximately every 8 weeks thereafter", 
            "measure": "Determine the efficacy of KPT-330 (selinexor) by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD), assessed according to RECIST 1.1 criteria).", 
            "safety_issue": "No", 
            "time_frame": "At least 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02025985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety assessments will be based on adverse events, laboratory data, concomitant medications, and the results of physical examinations and vital signs.", 
            "measure": "Evaluate safety and tolerability.", 
            "safety_issue": "Yes", 
            "time_frame": "During treatment and 30 days after treatment."
        }, 
        "source": "Karyopharm Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Karyopharm Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}